282 related articles for article (PubMed ID: 28356518)
1. BCL6 promotes glioma and serves as a therapeutic target.
Xu L; Chen Y; Dutra-Clarke M; Mayakonda A; Hazawa M; Savinoff SE; Doan N; Said JW; Yong WH; Watkins A; Yang H; Ding LW; Jiang YY; Tyner JW; Ching J; Kovalik JP; Madan V; Chan SL; Müschen M; Breunig JJ; Lin DC; Koeffler HP
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3981-3986. PubMed ID: 28356518
[TBL] [Abstract][Full Text] [Related]
2. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
4. MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis.
Srivastava S; Makala H; Sharma V; Suri V; Sarkar C; Kulshreshtha R
Cell Mol Life Sci; 2022 Jan; 79(2):104. PubMed ID: 35091793
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
[TBL] [Abstract][Full Text] [Related]
6. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL.
Yan J; Xu C; Li Y; Tang B; Xie S; Hong T; Zeng E
J Cell Mol Med; 2019 Aug; 23(8):5518-5531. PubMed ID: 31240814
[TBL] [Abstract][Full Text] [Related]
9. PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway.
Sun J; Xu Y; Liu J; Cui H; Cao H; Ren J
Cancer Sci; 2022 Feb; 113(2):500-516. PubMed ID: 34812552
[TBL] [Abstract][Full Text] [Related]
10. Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility.
Yu M; Li W; Wang Q; Wang Y; Lu F
Oncogene; 2018 Aug; 37(35):4838-4853. PubMed ID: 29773903
[TBL] [Abstract][Full Text] [Related]
11. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma.
Yen SY; Chuang HM; Huang MH; Lin SZ; Chiou TW; Harn HJ
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208648
[TBL] [Abstract][Full Text] [Related]
12. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis.
Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831142
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion.
Yen SY; Chen SR; Hsieh J; Li YS; Chuang SE; Chuang HM; Huang MH; Lin SZ; Harn HJ; Chiou TW
Oncogene; 2016 Apr; 35(17):2156-65. PubMed ID: 26257061
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Song W; Wang Z; Kan P; Ma Z; Wang Y; Wu Q; Yao X; Zhang B
Biomed Res Int; 2018; 2018():6953506. PubMed ID: 30420967
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
16. Quercetin Induces Apoptosis in Glioblastoma Cells by Suppressing Axl/IL-6/STAT3 Signaling Pathway.
Kim HI; Lee SJ; Choi YJ; Kim MJ; Kim TY; Ko SG
Am J Chin Med; 2021; 49(3):767-784. PubMed ID: 33657989
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
18. The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.
Fabre MS; Stanton NM; Slatter TL; Lee S; Senanayake D; Gordon RMA; Castro ML; Rowe MR; Taha A; Royds JA; Hung N; Melnick AM; McConnell MJ
PLoS One; 2020; 15(4):e0231470. PubMed ID: 32320427
[TBL] [Abstract][Full Text] [Related]
19. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.
Hutterer M; Knyazev P; Abate A; Reschke M; Maier H; Stefanova N; Knyazeva T; Barbieri V; Reindl M; Muigg A; Kostron H; Stockhammer G; Ullrich A
Clin Cancer Res; 2008 Jan; 14(1):130-8. PubMed ID: 18172262
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
